Proposed strategies for successful clinical management with aripiprazole

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1279-1290

  Mago, Rajnish ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adverse effects; Aripiprazole; Bipolar disorder; Dosing strategy; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZATROPINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; GINGER EXTRACT; HALOPERIDOL; LORAZEPAM; METOCLOPRAMIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PROPRANOLOL; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADJUVANT THERAPY; AGITATION; AKATHISIA; AMENORRHEA; ANXIETY; ANXIETY DISORDER; BEDTIME DOSAGE; BINDING AFFINITY; BIPOLAR I DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSOMNIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MEDLINE; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TARDIVE DYSKINESIA; TREMOR; VOMITING; WEIGHT GAIN; DOSE RESPONSE; DRUG ADMINISTRATION; MENTAL DISEASE; PRACTICE GUIDELINE; TITRIMETRY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENTAL DISORDERS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; QUINOLONES; TITRIMETRY; TREATMENT OUTCOME;

EID: 45549098860     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1279     Document Type: Review

References (75)

1. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11
2. 2 receptors. J Pharmacol Exp Ther 2002;302:381-9
3. 1A receptor. Eur J Pharmacol 2002;441:137-40
4. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53
5. 2A receptor blockade. CNS Neurol Disord Drug Targets 2006; 5:445-52
6. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-83
7. Otsuka Pharmaceutical Company, Ltd. Abilify® Prescribing Information. Tokyo: Otsuka Pharmaceutical Company Ltd.; 2006
8. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36
9. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71
10. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
11. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
12. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56
13. Keck PE Jr, Marcus R, Tourkodimitris S, et al. Aripiprazole Study Group. A placebo controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8
14. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536-46
15. Vieta E, Bourin M, Sanchez R, et al. Aripiprazole Study Group. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br J Psychiatry 2005;187:235-42
16. Keck JR PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37
17. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressivedisorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843-53
18. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:156-65
19. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
20. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88(1-3):63-72.
21. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
22. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
23. Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole. Int J Neuropsychopharmacol 2002;5(Suppl):S186
24. Stock E, Saha A, Brunell R, et al. Meta-analysis of cardiac safety with aripiprazole. Int J Neuropsychopharmacol 2002;5(Suppl):S186
25. Carson W, Saha AR, Iwamoto T, et al. Meta-analysis of prolactin effects with aripiprazole. Int J Neuropsychopharmacol 2002;5(Suppl):S186
26. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
27. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-35
28. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81
29. Guo JJ, Keck JR PE, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry 2006;67:1055-61
30. Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 1998;10:209-22
31. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Available from: http://www.psych.org/ psych_pract/treatg/pg/prac_guide.cfm [Last accessed 6 October 2006]
32. Geodon® Prescribing Information. New York: Pfizer Inc.; 2005
33. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia: relationship to course and outcome. Arch Gen Psychiatry 1990;47:228-36
34. Boteva K, Lieberman J. Reconsidering the classification of schizophrenia and manic depressive illness - a critical analysis and new conceptual model. World J Biol Psychiatry 2003;4:81-92
35. Mcintyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006;57:1140-4
36. Sajatovic M, Blow FC, Ignacio RV. Psychiatric comorbidity in older adults with bipolar disorder. Int J Geriatr Psychiatry 2006;21:582-7
37. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 2006;21:1133-7
38. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67(Suppl 9):25-30
39. Masi G, Perugi G, Toni C, et al. Attention-deficit hyperactivity disorder - bipolar comorbidity in children and adolescents. Bipolar Disord 2006;8:373-81
40. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl 18):47-56
41. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(Suppl 23):5-12
42. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-91
43. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735-44
44. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-63
45. Reddymasu S, Bahta E, Levine S, et al. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP 2006;7:303-5
46. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005;22:1440-3
47. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007;33:823-30
48. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821-5
49. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-5
50. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35(Suppl):S75-86
51. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004;65:1491-8
52. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:714-7
53. Casey DE. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol 1997;12(Suppl 1):S19-27
54. Brown ES, Jeffress J, Liggin JDM, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66:756-60
55. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
56. National Institute for Clinical Excellence Guidelines (NICE). Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care. London: National Collaborating Center for Mental Health, Royal College of Psychiatrists' Research Unit; 2003. p. 1-264
57. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59:485-95
58. Keck PE, Perlis RH, Otto MW, et al. The Expert Consensus Guideline Series. Treatment of bipolar disorder. Available from: http://www.psychguides.com/ecgs15.php [Last accessed 6 October 2006]
59. Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23:1733-44
60. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berlin) 2003;166:391-9
61. De Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-73
62. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005;19:27-42
63. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:121-9
64. Remington G, Chue P, Stip E, et al. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005;76:267-72
65. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208
66. Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006;11:691-702
67. (1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007;164:1411-7
68. Weiden PJ, Aquila R, Dalheim L, et al. Switching antipsychotic medications. J Clin Psychiatry 1997;58(Suppl 10):63-72
69. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:236-9
70. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 2005;10:141-8
71. Barzman DH, Delbello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 2004;14:593-600
72. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Safety 2000;22:73-81
73. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12-21
74. Bone ME, Wilkinson DJ, Young JR, et al. Ginger root - a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia 1990;45:669-71
75. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reproduct Biol 1991;38:19-24